ABSTRACT
Colon cancer is one of the leading tumours in the world and it is considered among the big killers, together with lung, prostate and breast cancer. In the recent years very important advances occurred in the field of treatment of this frequent disease: adjuvant chemotherapy was demonstrated to be effective, chiefly in stage III patients, and surgery was optimized in order to achieve the best results with a low morbidity. Several new target-oriented drugs are under evaluation and some of them (cetuximab and bevacizumab) have already exhibited a good activity/efficacy, mainly in combination with chemotherapy. The development of updated recommendations for the best management of these patients is crucial in order to obtain the best results, not only in clinical research but also in every-day practice. This report summarizes the most important achievements in this field and provides the readers useful suggestions for their professional practice.
Subject(s)
Carcinoma , Colonic Neoplasms , Animals , Antineoplastic Combined Chemotherapy Protocols , Carcinoma/diagnosis , Carcinoma/epidemiology , Carcinoma/etiology , Carcinoma/therapy , Colonic Neoplasms/diagnosis , Colonic Neoplasms/epidemiology , Colonic Neoplasms/etiology , Colonic Neoplasms/therapy , Humans , Incidence , Neoplasm Staging/methods , Palliative Care , Prognosis , Survival AnalysisABSTRACT
Colorectal cancer (CRC) is one of the most common cancers in the Western world, with > 500,000 new cases diagnosed each year. One of the strongest risk factors for colon cancer is age. Physicians and their older patients commonly face the dilemma of whether to give/receive systemic chemotherapy for CRC. Evidence supports similar survival benefits with adjuvant and palliative chemotherapy in elderly patients compared with younger age groups. Data on treatment- related side effects did not reveal a different toxicity profile for elderly patients. The safety and efficacy of systemic chemotherapy in fit older patients were proven, and this group of patients could be enrolled in clinical trials. Conversely, frail older patients are more likely to suffer adverse outcomes when faced with stressors and might not benefit from chemotherapy. Despite a growing body of data, a great deal of work is still needed to establish optimal strategies to care for patients diagnosed with cancer later in life. There is a paucity of reports published in the literature because of the difficulty in routinely collecting such data. We report an overview of recent studies (clinical trials, pooled analysis, and population studies) to provide more information and to identify new and better treatment options.
Subject(s)
Colorectal Neoplasms/therapy , Age Factors , Aged , Antineoplastic Agents/therapeutic use , Clinical Trials as Topic , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/pathology , Humans , Palliative CareSubject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents, Alkylating/adverse effects , Neoplasms, Second Primary/chemically induced , Organoplatinum Compounds/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/chemically induced , Sigmoid Neoplasms/drug therapy , Adenocarcinoma/surgery , Aged , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cerebral Hemorrhage/etiology , Combined Modality Therapy , Fatal Outcome , Female , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , Neoplasms, Second Primary/complications , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Sigmoid Neoplasms/surgeryABSTRACT
OBJECTIVE: Combination therapies of fluorouracil (FU) with irinotecan (CPT-11) and docetaxel plus cisplatin have been proven to be active in metastatic gastric cancer. In this paper, we present the results of a phase III trial in which these two combinations given sequentially were compared to mitomycin C (MMC) monochemotherapy in an adjuvant setting. METHODS: 169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B). All patients had histologically confirmed gastric carcinoma with nodal positivity or pT3/4. A total of 166 patients (85 in arm A and 81 in arm B) were treated. Adjuvant treatment was completed in 76% of the patients in arm A and in 70% of the patients in arm B. The main grade 3/4 side effects recorded were neutropenia in 35%, with only 1 febrile patient, and diarrhea in 11% in arm A, and thrombocytopenia in 10% and neutropenia in 7% in arm B. The FOLFIRI regimen and docetaxel/cisplatin given in sequence was well tolerated and feasible in adjuvant setting. This sequence treatment currently represents the experimental arm of an ongoing multicenter trial.